Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates.

Rower JE, Anderson DJ, Sherwin CM, Reilly CA, Ballard PL, McEvoy CT, Wilkins DG.

J Pharm Biomed Anal. 2019 Jan 29;167:7-14. doi: 10.1016/j.jpba.2019.01.048. [Epub ahead of print]

PMID:
30738243
2.

Correction: Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia.

Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D; TOLSURF Study Group.

Pediatr Res. 2019 Feb 7. doi: 10.1038/s41390-019-0314-y. [Epub ahead of print]

PMID:
30733615
3.

Outcome of surgical management for midurethral sling complications: a multicentre retrospective cohort study.

Kershaw V, Nicholson R, Ballard P, Khunda A, Puthuraya S, Gouk E.

Int Urogynecol J. 2019 Jan 7. doi: 10.1007/s00192-018-3853-6. [Epub ahead of print]

PMID:
30617507
4.

Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature.

Khunda A, McCormick C, Ballard P.

Int Urogynecol J. 2018 Dec 7. doi: 10.1007/s00192-018-3841-x. [Epub ahead of print]

PMID:
30535791
5.

Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia.

Lewis T, Truog W, Norberg M, Ballard PL, Torgerson D; TOLSURF Study Group.

Pediatr Res. 2018 Nov 22. doi: 10.1038/s41390-018-0235-1. [Epub ahead of print] Erratum in: Pediatr Res. 2019 Feb 7;:.

PMID:
30467342
6.

Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth.

Hamvas A, Feng R, Bi Y, Wang F, Bhattacharya S, Mereness J, Kaushal M, Cotten CM, Ballard PL, Mariani TJ; PROP Investigators.

BMC Genet. 2018 Oct 20;19(1):94. doi: 10.1186/s12863-018-0679-7.

7.

Mesoscale surface plasmons: modelling and imaging using near-field scanning optical microscopy.

Mayevsky AD, Davis TJ, Ballard PM, Henderson CA, Funston AM.

Opt Express. 2018 Sep 3;26(18):23426-23435. doi: 10.1364/OE.26.023426.

PMID:
30184843
8.

Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment.

Ballard PL, Keller RL, Truog WE, Chapin C, Horneman H, Segal MR, Ballard RA; Tolsurf Investigators.

Pediatr Res. 2018 Aug 15. doi: 10.1038/s41390-018-0144-3. [Epub ahead of print]

PMID:
30140069
9.

Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants.

Torgerson DG, Ballard PL, Keller RL, Oh SS, Huntsman S, Hu D, Eng C, Burchard EG, Ballard RA; TOLSURF Study Group.

Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L858-L869. doi: 10.1152/ajplung.00073.2018. Epub 2018 Aug 16.

PMID:
30113228
10.

Reply.

Ballard RA, Ballard PL, Askie LM, Schreiber MD, Hibbs AM, Torgerson DG, Keller RL.

J Pediatr. 2018 Oct;201:300-301. doi: 10.1016/j.jpeds.2018.06.039. Epub 2018 Jul 18. No abstract available.

PMID:
30029868
11.

Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial.

Wai KC, Hibbs AM, Steurer MA, Black DM, Asselin JM, Eichenwald EC, Ballard PL, Ballard RA, Keller RL; Trial of Late Surfactant (TOLSURF) Study Group.

J Pediatr. 2018 Jul;198:201-208.e3. doi: 10.1016/j.jpeds.2018.02.032. Epub 2018 Apr 4.

PMID:
29627188
12.

Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.

Pilla Reddy V, Walker M, Sharma P, Ballard P, Vishwanathan K.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):321-330. doi: 10.1002/psp4.12289. Epub 2018 Mar 15.

13.

Impacts of Adolescent and Young Adult Civic Engagement on Health and Socioeconomic Status in Adulthood.

Ballard PJ, Hoyt LT, Pachucki MC.

Child Dev. 2018 Jan 23. doi: 10.1111/cdev.12998. [Epub ahead of print]

PMID:
29359473
14.

Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis.

Askie LM, Davies LC, Schreiber MD, Hibbs AM, Ballard PL, Ballard RA.

J Pediatr. 2018 Feb;193:34-39.e2. doi: 10.1016/j.jpeds.2017.10.004. Epub 2017 Dec 11.

PMID:
29241680
15.

Digital Media, Participatory Politics, and Positive Youth Development.

Middaugh E, Clark LS, Ballard PJ.

Pediatrics. 2017 Nov;140(Suppl 2):S127-S131. doi: 10.1542/peds.2016-1758Q. Review.

16.

One normal void and residual following MUS surgery is all that is necessary in most patients.

Ballard P, Shawer S, Anderson C, Khunda A.

Int Urogynecol J. 2018 Apr;29(4):563-569. doi: 10.1007/s00192-017-3449-6. Epub 2017 Sep 4.

PMID:
28871439
17.

Intervention to maximise the probability of epidemic fade-out.

Ballard PG, Bean NG, Ross JV.

Math Biosci. 2017 Nov;293:1-10. doi: 10.1016/j.mbs.2017.08.003. Epub 2017 Aug 10.

PMID:
28804021
18.

Longitudinal Links Between Discrimination and Civic Development Among Latino and Asian Adolescents.

Ballard PJ.

J Res Adolesc. 2016 Dec;26(4):723-737. doi: 10.1111/jora.12221. Epub 2015 Sep 22.

PMID:
28453198
19.

Commentary on the identity of fibroblast pneumocyte factor: rat vs. human.

Ballard PL.

Pediatr Res. 2017 Jul;82(1):4-5. doi: 10.1038/pr.2017.85. Epub 2017 May 31. No abstract available.

20.

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.

Keller RL, Eichenwald EC, Hibbs AM, Rogers EE, Wai KC, Black DM, Ballard PL, Asselin JM, Truog WE, Merrill JD, Mammel MC, Steinhorn RH, Ryan RM, Durand DJ, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, Helderman J, Porta NF, Wadhawan R, Palermo L, Ballard RA; TOLSURF Study Group.

J Pediatr. 2017 Apr;183:19-25.e2. doi: 10.1016/j.jpeds.2016.12.059. Epub 2017 Jan 16.

21.

Action Civics for Promoting Civic Development: Main Effects of Program Participation and Differences by Project Characteristics.

Ballard PJ, Cohen AK, Littenberg-Tobias J.

Am J Community Psychol. 2016 Dec;58(3-4):377-390. doi: 10.1002/ajcp.12103.

22.

Antiinflammatory Effects of Budesonide in Human Fetal Lung.

Barrette AM, Roberts JK, Chapin C, Egan EA, Segal MR, Oses-Prieto JA, Chand S, Burlingame AL, Ballard PL.

Am J Respir Cell Mol Biol. 2016 Nov;55(5):623-632.

23.

Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns.

Wai KC, Kohn MA, Ballard RA, Truog WE, Black DM, Asselin JM, Ballard PL, Rogers EE, Keller RL; Trial of Late Surfactant (TOLSURF) Study Group.

J Pediatr. 2016 Oct;177:97-102.e2. doi: 10.1016/j.jpeds.2016.06.079. Epub 2016 Jul 26.

24.

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P.

Mol Cancer Ther. 2016 Oct;15(10):2378-2387. Epub 2016 Jul 20.

25.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D.

Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. Epub 2016 Jul 19.

26.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.

Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, Ballard P.

Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203. Epub 2016 May 25.

PMID:
27226351
27.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D'Cruz C, De Savi C.

Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.

28.

The probability of epidemic fade-out is non-monotonic in transmission rate for the Markovian SIR model with demography.

Ballard PG, Bean NG, Ross JV.

J Theor Biol. 2016 Mar 21;393:170-8. doi: 10.1016/j.jtbi.2016.01.012. Epub 2016 Jan 18.

PMID:
26796227
29.

Biological Sensitivity to Family Income: Differential Effects on Early Executive Functioning.

Obradović J, Portilla XA, Ballard PJ.

Child Dev. 2016 Mar-Apr;87(2):374-84. doi: 10.1111/cdev.12475. Epub 2015 Dec 28.

PMID:
26709089
30.

Expression of human carcinoembryonic antigen-related cell adhesion molecule 6 and alveolar progenitor cells in normal and injured lungs of transgenic mice.

Lin SE, Barrette AM, Chapin C, Gonzales LW, Gonzalez RF, Dobbs LG, Ballard PL.

Physiol Rep. 2015 Dec;3(12). pii: e12657. doi: 10.14814/phy2.12657. Epub 2015 Dec 22.

31.

Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.

Ballard RA, Keller RL, Black DM, Ballard PL, Merrill JD, Eichenwald EC, Truog WE, Mammel MC, Steinhorn RH, Rogers EE, Ryan RM, Durand DJ, Asselin JM, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, O'Shea TM, Porta NF, Wadhawan R, Palermo L; TOLSURF Study Group.

J Pediatr. 2016 Jan;168:23-9.e4. doi: 10.1016/j.jpeds.2015.09.031. Epub 2015 Oct 21.

32.

Engaging youth in communities: a framework for promoting adolescent and community health.

Ballard PJ, Syme SL.

J Epidemiol Community Health. 2016 Feb;70(2):202-6. doi: 10.1136/jech-2015-206110. Epub 2015 Oct 6.

PMID:
26443541
33.

Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials.

Roberts JK, Stockmann C, Dahl MJ, Albertine KH, Egan E, Lin Z, Reilly CA, Ballard PL, Ballard RA, Ward RM.

Curr Clin Pharmacol. 2016;11(1):53-61.

34.

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, Andrews DM, Ballard P, Buttar D, Callis RJ, Currie GS, Curwen JO, Davies CD, Donald CS, Feron LJ, Gingell H, Glossop SC, Hayter BR, Hussain S, Karoutchi G, Lamont SG, MacFaul P, Moss TA, Pearson SE, Tonge M, Walker GE, Weir HM, Wilson Z.

J Med Chem. 2015 Oct 22;58(20):8128-40. doi: 10.1021/acs.jmedchem.5b00984. Epub 2015 Oct 7.

PMID:
26407012
35.

Expression of Carcinoembryonic Cell Adhesion Molecule 6 and Alveolar Epithelial Cell Markers in Lungs of Human Infants with Chronic Lung Disease.

Gonzales LW, Gonzalez R, Barrette AM, Wang P, Dobbs L, Ballard PL.

J Histochem Cytochem. 2015 Dec;63(12):908-21. doi: 10.1369/0022155415603768. Epub 2015 Sep 15.

36.

Martius graft for TOT extrusion: a case series.

Mortimer A, Khunda A, Ballard P.

Int Urogynecol J. 2016 Jan;27(1):113-6. doi: 10.1007/s00192-015-2799-1. Epub 2015 Aug 7.

PMID:
26249238
37.

UK law on consent: the need for longer consultations.

Ballard PA.

BMJ. 2015 Jun 30;350:h3484. doi: 10.1136/bmj.h3484. No abstract available.

PMID:
26126664
38.

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Kettle JG, Ballard P, Bardelle C, Cockerill M, Colclough N, Critchlow SE, Debreczeni J, Fairley G, Fillery S, Graham MA, Goodwin L, Guichard S, Hudson K, Ward RA, Whittaker D.

J Med Chem. 2015 Mar 26;58(6):2834-44. doi: 10.1021/acs.jmedchem.5b00098. Epub 2015 Mar 12.

PMID:
25738750
39.

Surface film formation in vitro by infant and therapeutic surfactants: role of surfactant protein B.

Danhaive O, Chapin C, Horneman H, Cogo PE, Ballard PL.

Pediatr Res. 2015 Feb;77(2):340-6. doi: 10.1038/pr.2014.176. Epub 2014 Oct 31.

40.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL.

J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.

PMID:
25271963
41.

Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.

Ballard P, Swaisland HC, Malone MD, Sarda S, Ghiorghiu S, Wilbraham D.

Xenobiotica. 2014 Dec;44(12):1083-98. doi: 10.3109/00498254.2014.938257. Epub 2014 Jul 9.

PMID:
25007130
42.

Inhaled nitric oxide increases urinary nitric oxide metabolites and cyclic guanosine monophosphate in premature infants: relationship to pulmonary outcome.

Ballard PL, Keller RL, Black DM, Durand DJ, Merrill JD, Eichenwald EC, Truog WE, Mammel MC, Steinhorn R, Ryan RM, Courtney SE, Horneman H, Ballard RA; Investigators of TOLSURF Pilot and TOLSURF.

Am J Perinatol. 2015 Feb;32(3):225-32. doi: 10.1055/s-0034-1382255. Epub 2014 Jun 26.

43.

An integrative view of school functioning: transactions between self-regulation, school engagement, and teacher-child relationship quality.

Portilla XA, Ballard PJ, Adler NE, Boyce WT, Obradović J.

Child Dev. 2014 Sep-Oct;85(5):1915-31. doi: 10.1111/cdev.12259. Epub 2014 Jun 10.

44.

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D.

ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. eCollection 2013 Aug 8.

45.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

46.

Factors associated with pressure ulcer risk in spinal cord injury rehabilitation.

DeJong G, Hsieh CH, Brown P, Smout RJ, Horn SD, Ballard P, Bouchard T.

Am J Phys Med Rehabil. 2014 Nov;93(11):971-86. doi: 10.1097/PHM.0000000000000117.

PMID:
24879551
47.

Parents as the start of the solution: a social marketing approach to understanding triggers and barriers to entering a childhood weight management service.

Gillespie J, Midmore C, Hoeflich J, Ness C, Ballard P, Stewart L.

J Hum Nutr Diet. 2015 Jan;28 Suppl 1:83-92. doi: 10.1111/jhn.12237. Epub 2014 May 28.

PMID:
24866275
48.

Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice.

LaFemina MJ, Sutherland KM, Bentley T, Gonzales LW, Allen L, Chapin CJ, Rokkam D, Sweerus KA, Dobbs LG, Ballard PL, Frank JA.

Am J Respir Cell Mol Biol. 2014 Oct;51(4):550-8. doi: 10.1165/rcmb.2013-0456OC.

49.

Give It Up For Baby: outcomes and factors influencing uptake of a pilot smoking cessation incentive scheme for pregnant women.

Radley A, Ballard P, Eadie D, MacAskill S, Donnelly L, Tappin D.

BMC Public Health. 2013 Apr 15;13:343. doi: 10.1186/1471-2458-13-343.

50.

Acute rehospitalizations during inpatient rehabilitation for spinal cord injury.

Hammond FM, Horn SD, Smout RJ, Chen D, DeJong G, Scelza W, Jha A, Ballard PH, Bloomgarden J.

Arch Phys Med Rehabil. 2013 Apr;94(4 Suppl):S98-105. doi: 10.1016/j.apmr.2012.11.051.

PMID:
23527777

Supplemental Content

Loading ...
Support Center